EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Powder Systems Limited
Tendering Manager Asia-Pacific
Powder Systems Limited PSL has been exporting its technology to the AsiaPacific market since and a growing number of turnkey installations are to be commissioned in this region in the future To support the demand PSL has committed to further investment in AsiaPacific APAC by opening an engineering and sales office in Singapore This addition to PSL APAC will reinforce the fast growing activities c...
Articles
Synbiotics in Metabolic Health
Metabolic disorders have become a widespread epidemic globally posing one of the most significant public health challenges of the twentyfirst century The incidence rate ranges between to percent Ramesh et al The World Health Organization WHO projects that by around million individuals worldwide will develop metabolic disorders along with their associated complications van Hoogstraten et al
Research Insights
Discovery and Characterization of Anti-cancer Peptides from a Random Peptide Library
Cellpenetrating peptides are comprised of amino acids that function as carrier molecules to transduce various cargo molecules across cell membranes In the recent past several potential anticancer therapeutic peptides
Case Studies
Impact Of Substitution Among Generic Drugs On Persistence And Adherence:a Retrospective Claims Data Case Study
Abstract Once the period of exclusivity on a reference medicine expires it is possible to apply for marketing of a generic version of that medicine By definition a generic product is considered interchangeable with the innovator brand product when it demonstrates the same qualitative and quantitative composition in active substances the same pharmaceutical form and bi...
Techno Trends
Neurogene Introduces Breakthrough NGN-401 Gene Therapy for the Treatment of Rett Syndrome
Neurogene has introduced NGN for the treatment of patients with Rett syndrome a rare neurological disorder characterised by severe developmental and functional impairments
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Role of Nutraceutical in Various Diseases - A Review
Shaikh Habeeba working as an assistant professor at matoshri institute of pharmacy dhanore yeola nashik Maharashtra India. She has completed post-graduation in pharmacognosy. Her area of research interest in herbal formulation development. She has published more than 20 research& review paper in various national international journal. One case study accepted as book chapter in international publication & attended 17 conference & presented 5 paper in international national conference also guided more than 5 students for the research project.
Tiny Vesicles, Big Impact
Dr. Disha Marwaha received her PhD in biological sciences from CSIR-Central Drug Research Institute (CSIR-CDRI), India in 2024. She is currently an Assistant Professor at the GLA University, Mathura. She has more than 20 publications in international peer-reviewed Journals. She is an expert in formulation and development, nanomedicine and pharmacokinetics focusing on innovative therapeutic and targeted drug delivery systems.
Dr. Neha Singh received her Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI), India, in 2025. She is currently an Assistant Professor at the Lloyd School of Pharmacy, Greater Noida. Dr. Singh has contributed extensively to the field of pharmaceutical sciences, with many publications, patents, and book chapters in internationally recognised peer-reviewed journals. Her primary research interests include formulation development, nanomedicine and pharmacokinetics, with a focus on innovative therapeutic strategies and targeted drug delivery systems. Dr. Singh’s work reflects her commitment to advancing precision medicine and developing next-generation solutions for healthcare.
Moving from Code to Consequence
Dr. Sanjesh Kumar is an Assistant Professor at Chandigarh University Uttar Pradesh with a Ph.D. in Pharmacology. An award-winning academician specialized in neurodegenerative disorders and advanced drug delivery, he has authored over 45 high-impact publications and holds multiple patents, seamlessly bridging the gap between clinical research and classroom education.
Dr. Disha Marwaha earned a Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI) in 2024 and currently serves as an Assistant Professor at Chandigarh University Uttar Pradesh. Her research encompasses nanomedicine, pharmacokinetics, formulation development, and targeted drug delivery systems. She has authored more than 22 articles in peer-reviewed international journals.
Meaningful Advances in Virtual Cells
Brita Belli is an award-winning science and tech writer and Senior Manager of Communications at Recursion, a clinical-stage TechBio company. Her writing has been featured in the New York Times, National Geographic, MSN.com, and Alternet, and she has covered AI drug discovery and other health tech topics for Future Medicine AI, On Drug Delivery, European Biopharmaceutical Review, and OR Manager Magazine. She’s the author of The Autism Puzzle: Connecting the Dots Between Environmental Toxins and Rising Autism Rates (Seven Stories Press).
Why tier-2 and tier-3 cities are not included for clinical research
Co-Founder at DPHS Pvt. Ltd., Dr. Krutikesh Age is a researcher and a visionary committed towards propelling the field of clinical research and healthcare expansion in India. As the Co-founder of DPHS, Krutikesh manages varied key roles including Leadership, developing business and marketing strategies and Networking to name a few. It is through the deep understanding of clinical research and market dynamics that he has been instrumental in expanding the operations of DPHS in the past few years.
press releasesRead more...
Asia–US Clinical Data Collaboration Built on IHH's Clinical Data
Mitsui Co Ltd Mitsui Head Office Tokyo President and CEO Kenichi Hori has entered a service agreement with Oncoshot Pte Ltd Oncoshot on the utilization of Oncoshots proprietary clinical
Teijin, Teijin Regenet and Shinshu University Hospital Launch Joint Research to Strengthen CAR-T Cell Therapy Manufacturing Capabilities in Japan
Teijin Limited Teijin Regenet Co Ltd and Shinshu University Hospital today announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene
VVMF, Australia’s First Viral Vector CDMO Receives TGA Manufacturing Licence
Viral Vector Manufacturing Facility Pty Ltd VVMF Australias first viral vector Contract Development and Manufacturing Organisation CDMO advises that the Therapeutic Goods Administration TGA
Oral insulin drug achieves a critical milestone
University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers
Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies
Transcenta Therapeutics HKEX a global clinicalstage biopharmaceutical company with fully integrated capabilities in discovery RD and process development of antibodybased therapeutics
1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China
cBio a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases and Lees Pharmaceutical
EventsRead more...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
22 - 24
Sep 2026InsurInnovator Connect Asia
Singapore
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
CordenPharma Expands Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Annually
CordenPharma is expanding its sterile injectable manufacturing capacity at its Caponago site in Milan Italy through a multiyear investment programme
Exegenesis Bio Enters into Collaboration with Modalis to Advance MDL-201 for Duchenne Muscular Dystrophy
Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL an investigational treatment for Duchenne muscular dystrophy DMD
Schrödinger Forms Tectora Therapeutics to Advance Immunology and Inflammation Programmes
Schrdinger has announced the formation of Tectora Therapeutics The company was cofounded by Schrdinger New Enterprise Associates NEA and RA Capital Management
MannKind and Rose Pharma Partner to Develop Inhaled GLP-1 for Weight Management
MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE Technosphere an investigational inhaled GLP therapy for weight management
Rezubio Advances RZ-520 into Phase 1 Clinical Trial Following FDA and NMPA Clearances
Rezubio has announced the first cohort dosing in its Phase clinical trial of RZ following Investigational New Drug IND clearances from the US Food and Drug Administration FDA and Chinas National Medical
ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease
Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients